Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML

4 Dec 2019

Abstract excerpt

Abstract Despite advances in the treatment of acute myeloid leukemia (AML), prognosis of AML patients is still dismal and better treatment options are required. B-cell Lymphoma 2 (BCL-2) homology domain 3 (BH3)-mimetics are emerging as a novel class of apoptosis-inducing agents that are currently being tested for the treatment of different hematological malignancies including AML. Particularly, the selective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cell death mechanisms and regulation
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31801941
DOI: 10.1038/s41419-019-2156-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AMLPMID 31801941Read ↗

BH3 Mimetics in Hematologic MalignanciesSemantic proximity Read ↗

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.Semantic proximity Read ↗

BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the ClinicSemantic proximity Read ↗

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignanciesSemantic proximity Read ↗

BCL2 and MCL1 inhibitors for hematologic malignanciesSemantic proximity Read ↗

Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid LeukemiaSemantic proximity Read ↗

A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastomaSemantic proximity Read ↗

The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicineSemantic proximity Read ↗

AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens.Semantic proximity Read ↗

The BCL-2 arbiters of apoptosis and their growing role as cancer targetsSemantic proximity Read ↗

A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous LeukemiaSemantic proximity Read ↗

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.